Chinese expert consensus on monitoring and management of proteasome inhibitor-in-duced cardiovascular toxicity(2025 edition)
10.12354/j.issn.1000-8179.2025.20241375
- VernacularTitle:蛋白酶体抑制剂心血管毒性监测和管理中国专家共识(2025版)
- Author:
Liu TONG
;
Li YUE
- Collective Name:China Anti-Cancer Association,Integrated Oncocardiology Branch;Expert Panel on Chinese expert consensus on monitoring and man-agement of proteasome inhibitor-induced cardiovascular toxicity(2025 edition)
- Publication Type:Journal Article
- Keywords:
proteasome inhibitors(PIs);
cardiovascular toxicity;
multiple myeloma(MM)
- From:
Chinese Journal of Clinical Oncology
2025;52(4):163-171
- CountryChina
- Language:Chinese
-
Abstract:
Proteasome inhibitors(PIs)have become the backbone of combinatorial treatment regimens for patients with multiple myeloma(MM).The PIs-bortezomib,carfifilzomib,and ixazomib are all approved for treatment of MM.However,these drugs have shown a variety signs of cardiovascular toxicity,including heart failure,hypertension,arrhythmias,ischaemic heart disease,and thromboembolism,which in-crease patient risk associated with treatment,and negatively impact patient outcomes.Effective detection,monitoring,and management of PI-related cardiovascular toxicity are thus essential for improving clinical outcomes for patients with MM.This consensus proposes recom-mendations for the monitoring and management of cardiovascular toxicity related to PIs with the aim of standardizing their clinical applica-tion.
